Overall, two mechanisms of acquired SMO resistance in BCC have been delineate: 50% of inhibitor-resistant cases harbored mutations in the drug-binding site or sequence variants disrupting autoinhibition, thereby causing constitutive SMO activity [9]. This evidence concerns the gene SMO and skin basal cell carcinoma.